This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Subscribe To Our Newsletter & Stay Updated
